Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease (CD).

Filgotinib is a highly selective, Janus kinase 1 (JAK1) inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Crohn's disease is an inflammatory bowel disease (IBD) that causes the inflammation of the lining of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.

The inflammation often spreads deep into the layers of affected bowel tissue.

The Phase III DIVERSITY study is being conducted to assess the safety and efficacy of 100mg and 200mg filgotinib to be administered on a once-daily basis compared to placebo.

See Also:

"With the FITZROY Phase II study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn’s disease."

The study has enrolled 1,320 patients suffering from moderately to severely active Crohn’s disease, including those with prior biological therapy failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The start of the DIVERSITY study will also result to a $50m milestone payment from Gilead.

Galapagos chief scientific officer Dr Piet Wigerinck said: “With the FITZROY Phase II study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn’s disease.

“The start of the Phase III DIVERSITY study is good news for patients with Crohn’s disease.”

Last year, Galapagos and Gilead entered into a global collaboration to develop and commercialise filgotinib in inflammatory indications, under which the companies began a Phase III trial in rheumatoid arthritis (RA) and Crohn’s disease.